Atossa Hosts Key Opinion Leader Event on (Z)-Endoxifen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: PRnewswire
- Expert Participation: Atossa Therapeutics announced a virtual key opinion leader event on May 19, 2026, featuring internationally recognized surgical oncologist Dr. Laura Esserman, aimed at discussing clinical and translational data supporting the development of (Z)-endoxifen for innovative breast cancer treatment.
- Therapeutic Potential: The company believes that (Z)-endoxifen may serve as more than a single-indication therapy, potentially becoming an endocrine therapy platform across multiple ER-positive breast cancer settings, a perspective that will be further validated through Dr. Esserman's insights.
- Clinical Research Outlook: The event will address various topics of interest to clinicians, investors, and potential strategic partners, emphasizing the significance of (Z)-endoxifen in personalized breast cancer treatment, which could attract more investment and collaboration opportunities.
- Knowledge Dissemination: The event will be conducted via Zoom, allowing participants to submit questions in advance, and a replay of the webinar will be available on the company's investor section of the website post-event, ensuring broad dissemination and access to information.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATOS
Wall Street analysts forecast ATOS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.970
Low
7.00
Averages
18.33
High
40.00
Current: 4.970
Low
7.00
Averages
18.33
High
40.00
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atossa's New Research Findings on DMD Treatment
- Publication Announcement: Atossa Therapeutics' manuscript titled '(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy' has been accepted by Degenerative Neurological and Neuromuscular Disease, highlighting the significance of utrophin in muscle stability and potentially offering new insights for DMD treatment.
- Mechanistic Exploration: The study indicates that (Z)-endoxifen may enhance utrophin expression and function, influencing multiple signaling pathways relevant to DMD, including PKC beta-1 signaling and calcium homeostasis, thereby providing new therapeutic options for DMD patients.
- Preclinical Evaluation Plans: Atossa plans to conduct preclinical evaluations in dystrophin-deficient models and develop biomarkers to monitor utrophin expression and localization, aiming to lay the groundwork for future clinical trials.
- Market Potential Analysis: Atossa's (Z)-endoxifen has received FDA orphan drug and Rare Pediatric Disease designations, which could lead to a Priority Review Voucher upon approval, indicating significant market potential, with past sales of such vouchers ranging from $100 million to $205 million over the last 18-24 months.
See More
Atossa's New Research Findings on DMD
- Publication Achievement: Atossa Therapeutics' manuscript titled '(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy' has been accepted for publication in Degenerative Neurological and Neuromuscular Disease, highlighting utrophin's compensatory role in the absence of dystrophin, potentially offering new avenues for DMD treatment.
- Mechanistic Insights: The study indicates that (Z)-endoxifen may enhance utrophin expression and function by influencing multiple signaling pathways, such as PKC beta-1 and estrogen receptor signaling, thereby supporting muscle cell stability and regeneration, which holds significant clinical application potential.
- Future Research Plans: The manuscript outlines next steps including preclinical evaluations in dystrophin-deficient models and the development of biomarkers focused on utrophin expression and localization to further validate its therapeutic effects.
- Market Potential: Atossa's (Z)-endoxifen has received FDA orphan drug and Rare Pediatric Disease designations, and upon approval, it may benefit from a Priority Review Voucher, with substantial market potential evidenced by past sales of such vouchers ranging from $100 million to $205 million over the last 18-24 months.
See More
Atossa Hosts Key Opinion Leader Event on (Z)-Endoxifen
- Expert Participation: Atossa Therapeutics announced a virtual key opinion leader event on May 19, 2026, featuring internationally recognized surgical oncologist Dr. Laura Esserman, aimed at discussing clinical and translational data supporting the development of (Z)-endoxifen for innovative breast cancer treatment.
- Therapeutic Potential: The company believes that (Z)-endoxifen may serve as more than a single-indication therapy, potentially becoming an endocrine therapy platform across multiple ER-positive breast cancer settings, a perspective that will be further validated through Dr. Esserman's insights.
- Clinical Research Outlook: The event will address various topics of interest to clinicians, investors, and potential strategic partners, emphasizing the significance of (Z)-endoxifen in personalized breast cancer treatment, which could attract more investment and collaboration opportunities.
- Knowledge Dissemination: The event will be conducted via Zoom, allowing participants to submit questions in advance, and a replay of the webinar will be available on the company's investor section of the website post-event, ensuring broad dissemination and access to information.
See More
Atossa Therapeutics Q1 Financial Results
- Loss per Share: Atossa Therapeutics reported a GAAP EPS of -$1.11 for Q1 2026, indicating ongoing challenges in profitability that could undermine investor confidence.
- Increased Operating Expenses: The total operating expenses for the three months ended March 31, 2026, reached $9.9 million, up $2.5 million from $7.4 million in the same period of 2025, reflecting rising costs that may impact future financial flexibility.
- Reasons for Expense Growth: The increase in operating expenses is primarily attributed to higher spending on research and marketing, suggesting that Atossa is preparing for future product launches and market expansion, but may exert pressure on cash flow in the short term.
- Financial Health Risks: The ongoing losses and rising operating expenses could lead to greater pressure on Atossa regarding financing and investor trust, potentially affecting its long-term strategic development and market competitiveness.
See More
Atossa Therapeutics Reports Q1 2026 Financial Results and Updates
- Significant R&D Progress: Atossa Therapeutics advanced its (Z)-endoxifen clinical development in Q1 2026, particularly for breast cancer and rare diseases like Duchenne Muscular Dystrophy and McCune-Albright Syndrome, securing FDA Orphan Drug and Rare Pediatric Disease designations, highlighting its potential in high unmet medical needs.
- Increased Operating Expenses: Total operating expenses for Q1 2026 reached $9.9 million, up $2.5 million from $7.4 million in Q1 2025, primarily driven by rising R&D and administrative costs, reflecting the company's ongoing investment in product development.
- R&D Expense Breakdown: Within R&D expenses, clinical and pre-clinical trial costs amounted to $3.718 million, a 35% increase from the previous year, indicating a significant commitment to new drug development, although overall R&D expenses also experienced fluctuations in other areas.
- Strong Financial Position: As of March 31, 2026, Atossa reported cash and cash equivalents of $31.718 million, a decrease from $41.299 million at the end of 2025, yet the company maintains a solid financial foundation to support future strategic plans and enhance shareholder value.
See More
Atossa Announces KARISMA Trial Results for Endoxifen in Breast Cancer Prevention
- Clinical Trial Results: Atossa Therapeutics published results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute, demonstrating that low-dose Endoxifen significantly reduced mammographic density (MBD), a key risk factor for breast cancer, with a 19.3% reduction at 1 mg and 26.5% at 2 mg, providing a new therapeutic option for future breast cancer risk reduction.
- Safety and Tolerability: The trial showed that the 1 mg dose of Endoxifen had a similar tolerability profile to placebo, with only 5 adverse events in the 1 mg group compared to 11 in the 2 mg group, indicating the potential for long-term use of low-dose Endoxifen and improved patient acceptance.
- Dose Selection Insights: The study revealed that significant MBD reduction occurred at plasma concentrations of 3-4 ng/mL, with more prominent adverse effects at higher concentrations, providing crucial insights for future prevention studies and supporting the 1 mg dose as the preferred candidate.
- Strategic Implications: Atossa believes these results strengthen the rationale for advancing Endoxifen as a potential MBD reduction therapy, particularly for women with elevated MBD who may be hesitant to use current options, signaling new opportunities in the breast cancer prevention landscape.
See More
Atossa's New Research Findings on DMD Treatment
- Publication Announcement: Atossa Therapeutics' manuscript titled '(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy' has been accepted by Degenerative Neurological and Neuromuscular Disease, highlighting the significance of utrophin in muscle stability and potentially offering new insights for DMD treatment.
- Mechanistic Exploration: The study indicates that (Z)-endoxifen may enhance utrophin expression and function, influencing multiple signaling pathways relevant to DMD, including PKC beta-1 signaling and calcium homeostasis, thereby providing new therapeutic options for DMD patients.
- Preclinical Evaluation Plans: Atossa plans to conduct preclinical evaluations in dystrophin-deficient models and develop biomarkers to monitor utrophin expression and localization, aiming to lay the groundwork for future clinical trials.
- Market Potential Analysis: Atossa's (Z)-endoxifen has received FDA orphan drug and Rare Pediatric Disease designations, which could lead to a Priority Review Voucher upon approval, indicating significant market potential, with past sales of such vouchers ranging from $100 million to $205 million over the last 18-24 months.
See More
Atossa's New Research Findings on DMD
- Publication Achievement: Atossa Therapeutics' manuscript titled '(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy' has been accepted for publication in Degenerative Neurological and Neuromuscular Disease, highlighting utrophin's compensatory role in the absence of dystrophin, potentially offering new avenues for DMD treatment.
- Mechanistic Insights: The study indicates that (Z)-endoxifen may enhance utrophin expression and function by influencing multiple signaling pathways, such as PKC beta-1 and estrogen receptor signaling, thereby supporting muscle cell stability and regeneration, which holds significant clinical application potential.
- Future Research Plans: The manuscript outlines next steps including preclinical evaluations in dystrophin-deficient models and the development of biomarkers focused on utrophin expression and localization to further validate its therapeutic effects.
- Market Potential: Atossa's (Z)-endoxifen has received FDA orphan drug and Rare Pediatric Disease designations, and upon approval, it may benefit from a Priority Review Voucher, with substantial market potential evidenced by past sales of such vouchers ranging from $100 million to $205 million over the last 18-24 months.
See More
Atossa Hosts Key Opinion Leader Event on (Z)-Endoxifen
- Expert Participation: Atossa Therapeutics announced a virtual key opinion leader event on May 19, 2026, featuring internationally recognized surgical oncologist Dr. Laura Esserman, aimed at discussing clinical and translational data supporting the development of (Z)-endoxifen for innovative breast cancer treatment.
- Therapeutic Potential: The company believes that (Z)-endoxifen may serve as more than a single-indication therapy, potentially becoming an endocrine therapy platform across multiple ER-positive breast cancer settings, a perspective that will be further validated through Dr. Esserman's insights.
- Clinical Research Outlook: The event will address various topics of interest to clinicians, investors, and potential strategic partners, emphasizing the significance of (Z)-endoxifen in personalized breast cancer treatment, which could attract more investment and collaboration opportunities.
- Knowledge Dissemination: The event will be conducted via Zoom, allowing participants to submit questions in advance, and a replay of the webinar will be available on the company's investor section of the website post-event, ensuring broad dissemination and access to information.
See More
Atossa Therapeutics Q1 Financial Results
- Loss per Share: Atossa Therapeutics reported a GAAP EPS of -$1.11 for Q1 2026, indicating ongoing challenges in profitability that could undermine investor confidence.
- Increased Operating Expenses: The total operating expenses for the three months ended March 31, 2026, reached $9.9 million, up $2.5 million from $7.4 million in the same period of 2025, reflecting rising costs that may impact future financial flexibility.
- Reasons for Expense Growth: The increase in operating expenses is primarily attributed to higher spending on research and marketing, suggesting that Atossa is preparing for future product launches and market expansion, but may exert pressure on cash flow in the short term.
- Financial Health Risks: The ongoing losses and rising operating expenses could lead to greater pressure on Atossa regarding financing and investor trust, potentially affecting its long-term strategic development and market competitiveness.
See More
Atossa Therapeutics Reports Q1 2026 Financial Results and Updates
- Significant R&D Progress: Atossa Therapeutics advanced its (Z)-endoxifen clinical development in Q1 2026, particularly for breast cancer and rare diseases like Duchenne Muscular Dystrophy and McCune-Albright Syndrome, securing FDA Orphan Drug and Rare Pediatric Disease designations, highlighting its potential in high unmet medical needs.
- Increased Operating Expenses: Total operating expenses for Q1 2026 reached $9.9 million, up $2.5 million from $7.4 million in Q1 2025, primarily driven by rising R&D and administrative costs, reflecting the company's ongoing investment in product development.
- R&D Expense Breakdown: Within R&D expenses, clinical and pre-clinical trial costs amounted to $3.718 million, a 35% increase from the previous year, indicating a significant commitment to new drug development, although overall R&D expenses also experienced fluctuations in other areas.
- Strong Financial Position: As of March 31, 2026, Atossa reported cash and cash equivalents of $31.718 million, a decrease from $41.299 million at the end of 2025, yet the company maintains a solid financial foundation to support future strategic plans and enhance shareholder value.
See More
Atossa Announces KARISMA Trial Results for Endoxifen in Breast Cancer Prevention
- Clinical Trial Results: Atossa Therapeutics published results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute, demonstrating that low-dose Endoxifen significantly reduced mammographic density (MBD), a key risk factor for breast cancer, with a 19.3% reduction at 1 mg and 26.5% at 2 mg, providing a new therapeutic option for future breast cancer risk reduction.
- Safety and Tolerability: The trial showed that the 1 mg dose of Endoxifen had a similar tolerability profile to placebo, with only 5 adverse events in the 1 mg group compared to 11 in the 2 mg group, indicating the potential for long-term use of low-dose Endoxifen and improved patient acceptance.
- Dose Selection Insights: The study revealed that significant MBD reduction occurred at plasma concentrations of 3-4 ng/mL, with more prominent adverse effects at higher concentrations, providing crucial insights for future prevention studies and supporting the 1 mg dose as the preferred candidate.
- Strategic Implications: Atossa believes these results strengthen the rationale for advancing Endoxifen as a potential MBD reduction therapy, particularly for women with elevated MBD who may be hesitant to use current options, signaling new opportunities in the breast cancer prevention landscape.
See More
